J&J closes tender offer for Crucell
This article was originally published in Scrip
Executive Summary
Johnson & Johnson has completed its tender offer, worth about $2.4 billion (€1.75 billion), for the Dutch vaccine company Crucell, which as a result will function as the centre for vaccines within the J&J pharmaceuticals group.